Drug intelligence / Profile preview

Zevaria

Development stage: Preclinical
Lead developer: MiGenTra
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Zevaria is a monoclonal antibody biosimilar of bevacizumab, currently under development by MiGenTra for oncology indications. As an anti-VEGF-A antibody, it functions by binding to the Vascular Endothelial Growth Factor A (VEGF-A) protein, thereby preventing it from interacting with its receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells. This neutralization inhibits angiogenesis, the process of new blood vessel formation, which is critical for tumor growth and metastasis. MiGenTra is focusing on providing access to this and other biosimilars within the Middle East and Africa (MEA) region.

Brand names: Zevaria
Other names: bevacizumab biosimilar

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on Zevaria.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zevaria.

Explore the full profile